上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Nevanimibe (Synonyms: PD-132301; ATR-101)
Nevanimibe (PD-132301) 是一种口服有效的,选择性酰基辅酶 A:胆固醇 O-酰基转移酶 1 (ACAT1) 抑制剂,EC50 为 9 nM。Nevanimibe 抑制 ACAT2,EC50 为 368 nM。Nevanimibe 诱导细胞凋亡 (apoptosis),并具有抗肾上腺皮质癌的潜力。

Nevanimibe Chemical Structure
CAS No. : 133825-80-6
规格 | 是否有货 | ||
---|---|---|---|
100 mg | 询价 | ||
250 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
Nevanimibe 的其他形式现货产品:
生物活性 |
Nevanimibe (PD-132301) is an orally active and selective acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) inhibitor with an EC50 of 9 nM. Nevanimibe inhibits ACAT2 with an EC50 of 368 nM. Nevanimibe induces cell apoptosis and has the potential for adrenocortical cancer[1]. |
||||||||
---|---|---|---|---|---|---|---|---|---|
IC50 & Target |
|
||||||||
体外研究 (In Vitro) |
Coincubation of Nevanimibe (PD-132301; ATR101; 3 nM-30 μM) and Cholesterol markedly increases toxicity in a dose-dependent manner, where 3 nM Nevanimibe in the presence of 60 μg/mL Cholesterol reduces survival by 60% after 24 hours. All doses of Nevanimibe (3 nM-30 μM) induces cytoxicity in the presence of Cholesterol, whereas treatment with Cholesterol in the absence of Nevanimibe has no effect on cell viability[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cytotoxicity Assay[1]
|
||||||||
Clinical Trial |
|
||||||||
分子量 |
421.62 |
||||||||
Formula |
C27H39N3O |
||||||||
CAS 号 |
133825-80-6 |
||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||
储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis. |
||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务